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The non-Hodgkin’s lymphomas (NHL) are a heterogeneous group
of malignancies arising from B- or T-cell lymphatic systems. The
current REAL classification of lymphomas is based on histology,
immunohistochemistry and genetic changes (Harris et al 1994).
Several regulators of the cell cycle are currently well known and
their function and expression has been shown to be important 
in the initiation of cancer (Graña and Reddy, 1995; Hirama and
Koeffler, 1995; Sherr, 1996). Because of their importance in the
regulation of the cell cycle the presence and function of these regu-
lator proteins in specific malignancies needs to be further studied.
The cell cycle is regulated by cyclins, cyclin-dependent kinases
(CDK) and cyclin-CDK complex inhibitors. These inhibitory
proteins can be divided into two classes differing in both sequence
homology and their targets of inhibition (Hall et al, 1995). The CIP
(cyclin inhibitory protein)/KIP(kinase inhibitory protein) gene
family products (p21, p27 and p57) bind to cyclins, whereas INK4
gene family products (p15, p16, p18 and p19) bind to CDK4/6
(Graña and Reddy, 1995; Hall et al, 1995; Hirama and Koeffler,
1995; Sherr and Roberts, 1995; Sherr, 1996). Cyclin D and CDK
form complexes able to phosphorylate pRb protein which func-
tions in its hypophosphorylated form as a negative regulator of the
cell cycle during G1 phase. Cyclin D:CDK4/6 complexes phos-
phorylate retinoblastoma (RB) protein which then releases tran-
scription factors, and allows cells to enter the S phase. Mutations
of the RB gene or alterations in cyclin D:CDK complex inhibitory
genes lead to loss of the principal function of the Rb product –
growth control at G1/S border.
The expression of cyclin-dependent kinase inhibitor p27/Kip1,
a member of the p21 family, is high in cells inhibited by cell
contact, by the cytokine transforming growth factor-β (TGF-β ), or
by serum deprivation (Polyak et al, 1994). The present evidence
indicates that TGF-β induces cell cycle arrest through the cooper-
ative action of p15 and p27, or p21 (Reynisdóttir et al, 1995).
The non-Hodgkin’s lymphoma is a common malignancy, and its
incidence is increasing in older populations (Zheng et al, 1992).
Although NHL can be very invasive, treatments should not be
started until the NHL has been classified according to, e.g. the
REAL classification, since treatments vary considerably between
the subgroups. The classification of lymphomas is difficult and the
aggressiveness is variable within the same diagnosis. Therefore,
specific markers are needed to evaluate the aggressiveness of the
tumour and to improve the accuracy of classification. We have
studied proliferation status and the expression of p27 and pRb,
which are both cell cycle regulators involved in cyclin D-mediated
responses, by immunohistochemical staining in non-Hodgkin’s
lymphomas.
PATIENTS AND METHODS
The patient population included 96 non-Hodgkin’s lymphoma
(NHL) patients (age 16–90 years), who were treated at the Turku
University Central Hospital for various histological subtypes of 
B-cell non-Hodgkin’s lymphoma during years 1987–1996. The
patient group was heterogeneous consisting of either high (n = 52)
or low-grade (n = 44) malignant tumours. One representative
nodal block from each case was retrieved for investigation. The
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the REAL classification (Harris et al, 1994). All immunohisto-
chemistry was performed in Turku Central University Hospital
laboratory of pathology, which has been certificated by the Finnish
Medical Association, and is a member in an interlaboratory control
programme (Labquality, Helsinki, Finland).
Immunohistochemistry
The expression of cell cycle regulators p27, pRb and cell prolifer-
ation marker Ki-67 was investigated with immunohistochemistry
as follows:
p27 and pRb
The 96 tumour samples were fixed overnight with 10% neutral
buffer formalin and otherwise treated with standard pathology
laboratory methods used for routine lymphoma histopathology
specimens. Paraffin embedded tumour samples were then cut in 
5 µ m thick sections on silane-coated glass slides. The sections were
deparaffinized, rehydrated and treated for 5 min with 0.5% NP-40
(Sigma, St. Louis MO, USA) in TBS. For antigen retrieval the
slides were treated in a microwave oven by boiling in 10 mM
sodium citrate buffer (pH 6.0) for 10 min; after this, the slides were
allowed to soak in the hot buffer for an additional 20 min. The
tissue sections were then washed, blocked with normal serum and
incubated overnight at 4° C with monoclonal mouse anti-human
p27 antibody (Transduction Laboratories, Lexington, KY, USA) at
a 1:1000 dilution or with monoclonal mouse anti-human pRb anti-
body (PharMingen, San Diego CA, USA) at a 1:500 dilution. The
detection was performed with an anti-mouse ABC kit (Vector
Laboratories, Burlingame CA, USA). After 2 washes in TBS,
the samples were allowed to react with a biotinylated secondary
antibody at a 1:200 dilution for 30 min at room temperature and
ABC at a 1:75 dilution for 30 min at room temperature. The slides
were stained with diaminobenzidine, washed, counterstained with
Mayer’s haematoxylin, dehydrated, treated with xylene and
mounted with Mountex (Histolab Products AB, Sweden).
Both p27- and pRb-immunostainings were done in a single
batch to avoid run-to-run variability. Samples of normal tonsil
and retinoblastoma were included in each batch of stainings as
controls. Control sections were also processed without the primary
antibody to test the integrity of the staining procedure.
Ki-67
Immunohistochemistry for 96 samples was performed with
TechMate 500 (Dako, Denmark). From each of the selected
blocks, a 5-µ m tissue section was cut on a positively charged 
glass slide (ChemMate, DAKO A/S, Glostrup, Denmark). These
sections were then deparaffinized with xylene, rehydrated through
graded series of alcohol and washed three times with TBS. For
antigen retrieval, the samples were treated for 10 min in a
microwave oven in boiling 10 mM sodium citrate buffer, pH 6.0.
After boiling the slides were allowed to soak in the hot buffer at
room temperature for additional 20 min, and were then again
washed with TBS. Immunohistochemistry was performed in
an automated processor. Steps performed in the immunostainer
include blocking with normal horse serum, application of primary
antibody, application of secondary avidin-biotin-peroxidase-
conjugated antibody, development with 3,3-diaminobenzidine as a
substrate, and washes between each step. A light counterstaining
with Mayer’s haematoxylin was included. The primary mouse
monoclonal Ki-67/MIB-1 antibody (Immunotech, Marseille,
France) was applied for 27 min at a dilution of 1:200. All steps
were performed in room temperature with standardized reaction
times, allowing reliable comparison between the samples.
Interpretation of staining
The interpretation and the evaluation of immunohistochemical
staining results were performed blindly, and without reference to
the clinical history of the patients. All the stainings were evaluated
by two of the authors (MK and K-OS), and the classification is a
concensus of these evaluations. The samples from the same
tumour with different immunohistochemical stainings were evalu-
ated concurrently. Tumour samples were graded according to their
nuclear p27 and pRb staining into four groups (negative (0), low
(1), intermediate (2) and high (3) expression). In negative samples
staining was seen in benign cells, but not in malignant areas. In
low and intermediate staining less or more than 50% of the tumour
cells showed expression of p27 or pRb, respectively. Samples
were graded into the high-expression group when 75% or more of
the tumour cells were stained. Grading was based on the amount of
stained cells in tumour area. Observations included only tumour
cells excluding normal lymphocytes always present in lymphoid
tumours. The normal lymphocytes and stromal cells provided
internal positive and negative control in each sample. The few
samples with no positive labelling in either tumour cells or benign
cells were considered inconclusive and discarded from further
analysis, as they could not be reliably verified as negative tumours
due to the lack of internal positive control. The sample of
retinoblastoma, which served as pRb-negative control, showed no
staining for pRb but expressed p27 intensely. The section of tonsil
representing normal lymphoid tissue showed marked p27 staining,
while pRb expression was only seen in scattered cells in reactive
centres. No positive staining was observed in these control
sections when processed with exclusion of primary antibody.
Since the evaluation was based only on the number of stained
cells, any controls for levels of intensity were not in use. We chose
to evaluate the most intense area of staining instead of random
fields, because we believe that by assessing the area of highest
proliferation we have analysed the most biologically active
compartment of each tumour – the part which ultimately deter-
mines the prognosis of the patient and which also is the main target
of any cancer therapy. In addition, there were usually no great
differences in staining between different areas in tumours.
The tumour proliferating status was evaluated in Ki-67 (MIB-1)
stained samples by counting the percentage of labelled cells.
500–600 cells were counted from the area of most intense staining
in the sample. Cells were estimated as Ki-67 (MIB-1) positive if
they showed any staining in the nucleus.
Statistical analyses
Statistical analyses were performed using the SAS Release 6.12,
GLM-procedure program. To evaluate the expressions of p27 and
pRb against proliferating status of the samples (Ki-67 staining)
one-way analyses of variance (ANOVA) was computed. p27 and
pRb immunostainings were correlated with histological grade
(high-grade/low-grade) and subtype of lymphomas using Chi
Square test. The level of significance was set at P < 0.05.
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Low-grade malignancies (small lymphocytic B-cell and follicular
centre) showed intermediate or high expression of p27 in most
cases (40/44, 91%) (Table 1). Small lymphocytic B-cell lymphoma
samples showed a diffuse staining pattern throughout the sample
(15/15, 100%) (Figure 1A), whereas follicle centre lymphomas
showed marked p27 expression in the benign areas around folli-
cles and benign cells in follicular areas (25/29, 86%) (Figures 1C
and 1E).
High-grade malignancies showed more variation in p27 staining
(Table 1). Most high-grade malignancies (mantle cell and diffuse
large B-cell lymphoma) were negative or showed only very low
staining of p27 (38/52, 73%). In the group of most common 
high-grade malignancy, diffuse large B-cell lymphoma, only two
samples showed considerable expression for p27 (2/33, 6%)
(Figure 1G). The mantle cell lymphomas showed a very heteroge-
neous staining for p27 and were divided into all categories.
In most low-grade lymphomas the expression of pRb was weak
(39/44, 89%) (Table 2). The model of staining in small lympho-
cytic B-cell lymphomas was high expression of p27 and negative
expression of pRb in all of the samples (15/15, 100%) (Figure 1B)
whereas follicle centre lymphomas showed high expression of p27
but low or negative expression of pRb (23/29, 79%). In follicular
centre lymphomas marked pRb staining was only seen in follicle
areas, when benign tissue around follicles remained negative
(Figures 1D and 1F).
In tumour samples of diffuse large B-cell lymphomas pRb
staining was intense (31/40, 78%) (Figure 1H) (Table 2). In 
the group of mantle-cell lymphomas stainings divided into all cate-
gories as with p27 immunostaining. However, in mantle-cell
lymphoma samples with low p27 expression, pRb showed high
expression (7/7) whereas when pRb was lost, marked expression
of p27 was present (10/12, 83%). The inverse correlation between
p27 and pRb stainings in individual tumours can be clearly seen in
Tables 3 and 4.
The proliferative status of tumour samples investigated with 
Ki-67 (MIB-1) immunostaining was low in low-grade and high in
high-grade malignant tumours. The percentage of proliferating
cells analysed by Ki-67 (MIB-1) immunostaining increased as p27
expression was decreased (P < 0.0001, F = 12.01, ANOVA df = 3).
The opposite was seen when correlating pRb against Ki-67 
(P < 0.0001, F = 13.98, ANOVA df = 3) (Figure 2).
The comparison between low-grade malignancies (small
lymphocytic and follicular centre lymphomas, n = 44) and 
high-grade malignancies (diffuse large B-cell and mantle cell
lymphomas, n = 52) revealed that low-grade malignancies showed
higher expression of p27 than high-grade malignancies (P < 0.001,
Chi-square test, df = 3), and the pRb staining was dominant in
high-grade malignant samples (P < 0.001, Chi-square test, df = 3).
When comparing p27 and pRb expressions to histological grading
and proliferative activity (Ki-67 expression), coordinate changes
were observed in all subtypes of NHL (P < 0.05).
DISCUSSION
This study concentrated in observing changes in the most common
forms of lymphoma, i.e. diffuse large B-cell, mantle-cell, follicular
centre and small lymphocytic B-cell lymphoma, which in its
subsequent course is called chronic lymphocytic B-cell leukaemia.
The rarity of some lymphoma entities slows effective research in
these subgroups, e.g. the mantle-cell lymphoma, of which inci-
dence has increased recently. This could be due to more accurate
diagnostics using REAL classification. Clinical trials have failed
to significantly improve the outcome of patients with mantle-cell
lymphoma, and the disease leads to death in approximately 3 years
(Non-Hodgkin’s Lymphoma Classification Project, 1997). In the
present study the group of mantle-cell lymphomas produced the
most conflicting staining pattern. Although tumour samples
showed either marked p27 or pRb expression, they differed from
both low- and high-grade lymphoma groups according to their
stainings and therefore could not be characterized into either of
these groups in this study.
The role of cell cycle regulators has been a focus of cancer
research, and understanding of the initiation of cancer has
increased rapidly. In haematological malignancies several G1/S
checkpoint inhibitors have recently been under investigation. The
role of p16 gene alterations has been widely described, e.g. in adult
T-cell leukaemia and lymphoma (Uchida et al, 1998) and both B-
and T-cell lymphoid cell lines (Stranks et al, 1995). A recent
immunohistochemical study of p16 and pRb expressions in non-
Hodgkin’s lymphomas concluded a loss of these two proteins in
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Table 2 Relationship between pRb immunostaining and REAL classification
Number of tumours (%) Intensity
of SLBCL FCL MCL DLBCL
staining (n = 15) (n = 29) (n = 19) (n = 33)
0 12 (80) 8 (28) 6 (32) 2 (6)
1 3 (20) 16 (55) 4 (21) 4 (12)
2 0 (0) 5 (17) 1 (5) 11 (33)
3 0 (0) 0 (0) 8 (42) 16 (49)
SLBCL = small lymphocytic B-cell lymphoma; FCL = follicular-centre
lymphoma; MCL = mantle-cell lymphoma; DLBCL = diffuse large B-cell
lymphoma
Table 3 Inverse correlation between p27 and pRb expression in individual
tumour samples. Tumours with negative (0) or low (1) expression of p27
show marked expression of pRb, and vice versa
p27 0 1 2 3
pRB
02 0 7 1 9
12 3 6 1 6
27 6 3 1
31 3 9 2 0
Table 1 Relationship between p27 immunostaining and REAL classification
Number of tumours (%) Intensity 
of SLBCL FCL MCL DLBCL
staining (n = 15) (n = 29) (n = 19) (n = 33)
0 0 (0) 2 (7) 3 (16) 19 (58)
1 0 (0) 2 (7) 4 (21) 12 (36)
2 1 (7) 6 (20) 9 (47) 2 (6)
3 14 (93) 19 (66) 3 (16) 0 (0)
SLBCL = small lymphocytic B-cell lymphoma; FCL = follicular-centre
lymphoma; MCL = mantle-cell lymphoma; DLBCL = diffuse large B-cell
lymphoma1164 M Kiviniemi et al





Figure 1 All the stainings are counterstained with haematoxylin, the scale bar in the pictures is 25 µ m. Panels A, C, E and G immunohistochemically stained
for p27, panels B, D, F and H immunohistochemically stained for pRb. (A) A photomicrograph of a small lymphocytic lymphoma, case number 11. Almost all
lymphoma cells are strongly stained for p27. The blast cells are negative. (B) The Rb expresses only in blast cells in small lymphocytic lymphoma. (C) All
benign areas of follicle-centre lymphoma, case number 20, are strongly stained, note the high expression of p27 in mantle zone. (D) Inversely stained follicle of
follicular-centre lymphoma as compared to p27 staining. (E) A closer view of the same field of the follicular-centre lymphoma as seen in Figure 2. Normal
lymphocytes are p27-positive. (F) A closer view of the follicle in follicular-centre lymphoma showing strong pRb staining in blast cells. Note the positively stained
mitoses in the bottom of the field. (G) A diffuse large B-cell lymphoma, case number 95. Only normal lymphocytes show any p27 expression. (H) A strong
expression of pRb is seen in diffuse large B-cell lymphomahigh-grade malignant lymphomas but not in low-grade malignan-
cies (Geradts et al, 1998). The explanation for variance in our
results when compared to other studies investigating p27, pRb and
other cell cycle regulator proteins relates to differences in scoring
methods. While some groups (Geradts et al, 1998) have only
graded tumours to positive or negative, we chose to grade tumours
to four groups to increase the accuracy of evaluation. Also, in
some studies a larger part of the tumour has been graded, while we
concentrated the evaluation in the most intensely stained area,
seeking the most biologically active area of the tumour. In
immunohistochemical studies one also has to be critical for the
sensitiveness of the method. Some antibodies produce cytoplasmic
background, and it may interfere with reliable detection of nuclear
signals. The antibodies used in our study show only distinct
p27 and pRb in non-Hodgkin’s lymphomas 1165
British Journal of Cancer (2000) 83(9), 1161–1167 © 2000 Cancer Research Campaign
Table 4 p27, pRb and Ki-67 protein expression in individual tumours investigated by immunohistochemistry.
Protein expression Protein expression
Case by immunohistochemistry Case by immunohistochemistry
(low-grade) p27 pRb Ki-67(%) (high-grade) p27 pRb Ki67(%)
1 SLBCL +++ – 1 45 MCL ++ – 0
2 SLBCL +++ – 1 46 MCL + +++ 0
3 SLBCL ++ + 1 47 MCL +++ – 1
4 SLBCL +++ – 5 48 MCL +++ + 5
5 SLBCL +++ – 10 49 MCL ++ – 10
6 SLBCL +++ + 10 50 MCL +++ + 10
7 SLBCL +++ – 10 51 MCL ++ + 10
8 SLBCL +++ – 10 52 MCL ++ – 20
9 SLBCL +++ – 10 53 MCL ++ – 20
10 SLBCL +++ – 15 54 MCL + +++ 25
11 SLBCL +++ – 15 55 MCL + +++ 30
12 SLBCL +++ + 20 56 MCL ++ + 35
13 SLBCL +++ – 25 57 MCL – +++ 40
14 SLBCL +++ – 30 58 MCL ++ – 40
15 SLBCL +++ – 50 59 MCL ++ +++ 50
16 FCL +++ + 1 60 MCL ++ ++ 50
17 FCL +++ – 5 61 MCL + +++ 60
18 FCL ++ ++ 10 62 MCL – +++ 80
19 FCL +++ ++ 10 63 MCL – +++ 95
20 FCL +++ – 10 64 DLBCL – – 0
21 FCL + ++ 10 65 DLBCL + ++ 1
22 FCL ++ – 10 66 DLBCL + + 5
23 FCL +++ – 10 67 DLBCL – +++ 5
24 FCL +++ – 10 68 DLBCL – ++ 5
25 FCL +++ + 10 69 DLBCL – +++ 20
26 FCL +++ – 10 70 DLBCL ++ +++ 20
27 FCL +++ + 10 71 DLBCL – – 20
28 FCL +++ + 15 72 DLBCL – ++ 20
29 FCL +++ + 20 73 DLBCL + ++ 25
30 FCL ++ + 20 74 DLBCL – +++ 25
31 FCL ++ + 20 75 DLBCL – ++ 25
32 FCL + + 20 76 DLBCL – + 30
33 FCL +++ + 20 77 DLBCL + +++ 30
34 FCL +++ + 20 78 DLBCL – +++ 30
35 FCL +++ + 24 79 DLBCL + ++ 35
36 FCL +++ + 30 80 DLBCL – +++ 40
37 FCL – ++ 30 81 DLBCL + ++ 40
38 FCL +++ + 30 82 DLBCL + +++ 50
39 FCL +++ – 30 83 DLBCL + + 60
40 FCL ++ – 30 84 DLBCL – +++ 70
41 FCL +++ + 40 85 DLBCL ++ ++ 70
42 FCL ++ + 40 86 DLBCL + +++ 75
43 FCL – ++ 45 87 DLBCL – +++ 80
44 FCL +++ + 55 88 DLBCL + ++ 80
89 DLBCL – +++ 80
90 DLBCL – +++ 85
91 DLBCL – ++ 85
92 DLBCL + +++ 90
93 DLBCL – ++ 90
94 DLBCL – + 90
95 DLBCL – +++ 95
96 DLBCL + +++ 95
SLBCL = small lymphocytic B-cell lymphoma; FCL = follicular-centre lymphoma; MCL = mantle-cell lymphoma; DLBCL = diffuse large
B-cell lymphoma; (–) negative staining in malignant cells; (+) protein expression in less than 50% of malignant cells; (++) protein
expression in 50–75% of malignant cells; (+++) more than 75% of malignant cells show protein expression. Ki-67 expression in
percentage of 500–600 counted cellsnuclear staining, which was used as a basis of scoring.
Nevertheless, the comparison between different studies is possible
when one combines negative and low expressions to one group
and intermediate and high expressions to another group. Therefore
we claim, that the present study provides new knowledge with a
wider perspective of the G1/S checkpoint control in NHL.
Ki-67 (MIB-1) immunostaining has been commonly used as a
proliferation marker, and it is therefore appropriate as a correlation
against new molecular markers. Proliferative activity measured
with Ki-67 has been shown to act as a significant predictor of
survival in NHL (Mochen et al, 1997; Korkolopoulou et al, 1998).
p27 expression has previously been described to inversely relate 
to the proliferation index measured by Ki-67 in mantle-cell
lymphomas (Quintanilla-Martinez et al, 1998), whereas MALT-
NHLs have showed parallel expression for Ki-67 and pRb (Stefanaki
et al, 1998). Studies correlating the expression of Ki-67, p27 and pRb
in the same lymphomas have not been reported previously.
The results of p27 expression in correlation to tumour prognosis
have been conflicting in different malignancies. Decreased nuclear
expression of p27 has been shown to be a significant predictor of
poor survival in breast cancer (Catzavelos et al, 1997; Porter et al,
1997) and colorectal cancer (Yasui et al, 1997), whereas high
levels of p27 were associated with a shorter survival in chronic B-
cell lymphocytic leukaemia (Vrhovac et al, 1998). Homozygous
deletions or point mutations of p27 have been observed in adult T-
cell leukaemias and lymphomas (Hatta et al, 1997). The present
study revealed a significant correlation between p27 expression and
the grade and proliferative status of tumour. The presence of p27
protein, which functions as a cell cycle inhibitor, indicated lower
proliferative rate, which was characteristic of low-grade malignan-
cies. Loss of cell cycle inhibition as revealed by higher percentage
of Ki-67-positive cells and increased proliferative rate was observed
in most high-grade tumours, whereas p27 immunostaining was low
or undetectable among them. In low-grade lymphomas p27 staining
showed a marked resemblance to benign cells.
Mutations or loss of expression of pRb has been described to be
a cause of G1/S-checkpoint disruption in all common cancers.
NHL subtypes can be roughly arranged in linear order from the
lowest to the highest grade of malignancy (Harris et al, 1994;
Howard and Shipp, 1998; Zucca et al, 1998). When observing this
order of lymphomas, in the present study increase in both pRb and
Ki-67 expression from low- to high-grade malignancies was seen.
All samples of small lymphocytic lymphoma showed low expres-
sion of pRb, or were completely negative. This may be explained
by the fact that the malignant cells in small lymphocytic
lymphoma behave close to normal lymphocytes, which also have
low pRb expression. Similarly to our findings, there are recent
reports of high levels of pRb in high-grade malignant lymphomas
(Geradts et al, 1998; Cinti et al, 2000).
The main function of pRb is to act as a monitor of cell cycle
progression. pRb is phosphorylated by cyclin-D:CDK-complexes
at late G1 phase, and further phosphorylation is provided by other
cyclins until dephosphorylation after mitosis. We are convinced
that the immunohistochemically detected pRb represents both
hypo- and hyperphosphorylated protein, as even mitotic cells
stain positively (Figure 1F), and we have observed a positive
correlation between pRb expression and Ki-67 staining also in
benign proliferating tissues, such as skin, placenta and
endometrium (Sauroja et al, unpublished). In lymphatic B cells,
pRb may be needed for terminal differentation, as in pRb–/– mice
haemopoietic lineages fail to differentiate (Clarke et al, 1992; Lee
et al, 1992). On the other hand, in lymphatic malignancies the
growth-suppressive action of pRb may be overcome by overex-
pression of cyclin D, which has been shown in B-cell lymphomas
due to translocation t(11;14)(q13;q32) of the cyclin D gene
(Howard and Shipp, 1998). The regulation of cell cycle progres-
sion by pRb can also be disrupted by loss of control of cyclin:
CDK-complexes by either p16 or p21 families of cyclin-CDK-
inhibitors, such as the loss of p27 expression shown in the present
study. Furthermore, while the G1/S regulation by pRb is mediated
by binding to E2F family of transcription factors, later in the cell
cycle pRb can be bound by oncoproteins like c-Myc, c-Abl, and
MDM2 (Rustgi et al, 1991; Welch and Wang, 1993; Xiao et al,
1995). Considering all these mechanisms in the pRb pathway, our
finding of the apparently paradoxical correlation between pRb
expression and cell proliferation (Ki-67 expression) seems only
rational. Although it would be expected that tumours with high
levels of pRb had a reduced proliferative rate, observations
similar to ours have been reported recently (Leoncini et al, 1999;
Cinti et al, 2000).
In conclusion, this study showed coordinate changes in expres-
sion of p27 and pRb in non-Hodgkin’s lymphomas. The results
indicate that the differences in expression of p27 and pRb may
improve the evaluating of the aggressiveness of lymphomas.
Immunochemical stainings for p27 and pRb appeared to be useful
in differentiating between low- and high-grade lymphomas and
therefore may be suitable as tools for the lymphoma pathologist.
High-grade lymphomas expressed p27 significantly less than low-
grade malignancies, whereas the expression of pRb was dominant
in high-grade malignancies when the p27 control was lost.
Changes in control of cell cycle appeared to be closely related to
the pathobiology of non-Hodgkin’s lymphomas. Further studies
are needed to investigate whether prognostic significance of p27
and pRb expression can be found within specific non-Hodgkin’s
lymphoma types.
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Figure 2 The expression of Ki-67 (MIB-1) increases parallel to pRb and
inversely to p27 expressions. Stainings of p27 and pRb are presented as an
average of immunohistochemical staining scores in each subgroup (see also
Tables 3 and 4). Abbreviations and standard deviations in the Figure: SLBCL
= small lymphocytic B-cell lymphoma (SD p27 0.26, pRb 0.41), FCL =
follicular-centre lymphoma (SD p27 0.91, pRb 0.67), MCL = mantle cell
lymphoma (SD p27 0.95, pRb 1.35), DLBCL = diffuse large B-cell lymphoma
(SD p27 0.62, pRb 0.90)ACKNOWLEDGEMENTS
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